Skip to main content
TELO logo

TELO · Telomir Pharmaceuticals, Inc.

Track TELO — free
$1.14 -0.05 (-4.20%) At close · Aug 28
Market Cap
$78.40M
Shares
68.77M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income
-$10.41M +37%
FY2025 Net Income FY2022–FY2025
Diluted EPS
-$0.33 +41.1%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$3.69M +27.3%
FY2025 Operating Cash Flow FY2022–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022
$2.97M $2.44M $2.24M $1.57M $833.21K
$3.12M $8.1M $9.64M $600.19K $20.94K
$6.09M $10.54M $12.24M $3.94M $854.15K
$4.34M $1.64M
$214.1K $125.64K $48K
-$5.88M -$10.41M -$16.53M -$13.07M -$854.15K
USD/shares -$0.91 -$0.33 -$0.56 $0.48 -$0.03
USD/shares -$0.91 -$0.33 -$0.56 $0.48 -$0.03
shares 31.65M 29.54M 27.3M 26.83M
shares 31.65M 29.54M 27.3M 26.83M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Peer median 4.91×
EV/EBIT
Peer median 12.40×
P/E (TTM)
Peer median 10.58×

Peer medians compare against the 297 similar-size Biotechnology companies (of 524 listed).

Key facts CIK 1971532 CUSIP 87975F104 13F (30d) 28 filings 28 filers Visit website